On October 2^nd, NuCana completed its approximately $114 million initial public offering. United Kingdom-based NuCana is a clinical-stage company focused on improving treatment outcomes for patients with cancer by applying the company’s phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. The Underwriter syndicate on the IPO included Citigroup, Jefferies and Cowen as joint book-running managers, and William Blair as co-manager.

NuCana’s Mintz team on the IPO consisted of John Rudy, Bill Hicks, Bill Whelan, Adam Davey and Allyson Wilkinson, with Linda Bentley, Terri Shieh-Newton, Pam Greene, Roy Gillig, Avi Reshtick, Keerthika Subramanian and Mark Higgins, assisting in specialized areas.